SEC Comment Letter 0000000000-24-007642 to Ginkgo Bioworks Holdings, Inc. (DNA)

Ginkgo Bioworks Holdings, Inc.
Date: July 5, 2024 · CIK: 0001830214 · Accession: 0000000000-24-007642

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-40097

Date

July 5, 2024

Author

Jason Kelly

Form

UPLOAD

Company

Ginkgo Bioworks Holdings, Inc.

Letter

July 5, 2024 Jason Kelly Chief Executive Officer Ginkgo Bioworks Holdings, Inc. 27 Drydock Avenue 8th Floor Boston, MA 02210 Re:Ginkgo Bioworks Holdings, Inc. Revised Preliminary Proxy Statement on Schedule 14A Filed July 3, 2024 File No. 001-40097 Dear Jason Kelly: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Marko Zatylny

Show Raw Text

July 5, 2024
Jason Kelly
Chief Executive Officer
Ginkgo Bioworks Holdings, Inc.
27 Drydock Avenue
8th Floor
Boston, MA 02210
Re:Ginkgo Bioworks Holdings, Inc.
Revised Preliminary Proxy Statement on Schedule 14A
Filed July 3, 2024
File No. 001-40097
Dear Jason Kelly:
            We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Marko Zatylny

SecProbe.io